

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/539,670  
Confirmation No.: 4798  
Applicant: Gore, T. *et al.*  
Int'l File Date: December 18, 2003  
Group Art Unit: 1648  
Examiner: Sharon L. Hurt  
For: TRIVALENT VACCINE WITH MATERNAL ANTIBODY  
TRANSFER VIA THE MILK

June 20, 2007

**INFORMATION DISCLOSURE STATEMENT AND TRANSMITTAL  
OF FEE PURSUANT TO 37 CFR 1.97(b)**

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir/Madam:

To comply with 37 CFR §§1.97 and 1.98, Applicants submit the enclosed combined Form PTO/SB/08a, and a copy of the cited information (to the extent required by the Patent Office).

In accordance with MPEP §§609 and 707.05(b), Applicants request that the enclosed statement be given thorough consideration, and that the Examiner make the cited information of record by initialing the statement next to each citation. Applicants request such initialing even if the Examiner does not consider: (1) the cited information to be sufficiently pertinent to use in a rejection, or (2) the guidelines for a citation to have been fully satisfied. Applicants make this request so that the information will be cited on the face of a patent issuing from this patent application.

Applicants submit this statement in accordance with the duty to disclose information material to patentability under 37 CFR §1.56. Applicants, however, are not admitting that the information is necessarily relevant or prior art. In addition, Applicants are not representing that the cited information represents the results from a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104, and, in the course of such search, will review for relevance the cited information, even if not initialed.

Per the Patent Office's rules, Applicants have not enclosed any of the cited published U.S. patent references. Applicants, however, are happy to provide copies of any such references upon request from the Examiner. This statement is being submitted before the mailing of the first office action after filing of a request for continued examination under § 1.114. As such, Applicants believe that no IDS fee is needed.

Applicants do not believe that they owe any additional fee in connection with this filing. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge the fee(s) to Deposit Account No. **02-2334**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or 1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **02-2334**.

Appl. No: 10/539,670  
Information Disclosure Statement  
Attorney Docket No: 2002.025 US

Applicants submit that this patent application is in condition for allowance, and request that it be allowed. The Examiner is requested to call the Undersigned if any issues arise that can be addressed over the phone to expedite examination of this application.

Respectfully submitted,



---

Aaron L. Schwartz, PTO Reg. No: 48,181  
Patent Counsel

Intervet Inc.  
Patent Department  
P.O. Box 318  
29160 Intervet Lane  
Millsboro, DE 19966  
(302) 933-4034 (tel)  
(302) 934-4305 (fax)

ALS:dap